Precision experts Travis Harrison: VP, Bioassay Solutions (Precision for Medicine), Reed Lyon: Director, Business Development (Precision for Medicine), and Pallavi Chhabra: Director, Business Development (Precision for Medicine) will be exhibiting at ASGCT Annual from May 16-19 in Washington, D.C. Travis Harrison will also be giving a presentation on, “Key Considerations for Design and Implementation of Nab Bioassays in Gene Therapy Development” on May 17 at 1PM EST.

(more…)

The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers. Without proper solutions and partnerships, employers and health insurers will be held responsible for extreme medical costs associated with gene therapy.

(more…)

In recent years, the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new patient populations. 2021 saw record-breaking investments across the board, with a 16% increase from the previous year, totaling $23.1billion raised. However, the question remains as to whether this will continue in 2022. As public markets adjust and the economy recovers in early 2022, investments in the cell and gene therapy space may plateau.

(more…)

Advances in stem cell technology, combined with the increasing prevalence of chronic diseases, are driving rapid growth in the regenerative medicine category, which is predicted to generate $39.33 billion in revenue by 2023.

(more…)

The regenerative medicine category is predicted to generate $39.33 billion in revenue by 2023, with the fastest growth expected in cell therapy.

(more…)

“There’s a little over 1,200 clinical trials worldwide, and about half of those are in the US. Over 100 of those are in phase III, so we’re getting really close to getting more approved.”

(more…)